Eculizumab in atypical hemolytic-uremic syndrome [5]

New England Journal of Medicine

Volumn 369, Issue 14, 2013, Pages 1378-1379

  Tanimoto, Tetsuya ^a   Oshima, Yasuo ^b   Kami, Masahiro ^b  

^a Navitas Clinic   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C5; MONOCLONAL ANTIBODY;

DRUG ANTAGONISM; FEMALE; HEMOLYTIC UREMIC SYNDROME; HUMAN; MALE; NOTE; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANTIBODIES, MONOCLONAL, HUMANIZED; COMPLEMENT C5; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MALE; THROMBOTIC MICROANGIOPATHIES;

EID: 84884944270     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1308826     Document Type: Letter

References (11)

1. CM Legendre C Licht P Muus Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome N Engl J Med 368 2013 2169 2181
2. JM Thurman B Rohrer Noninvasive detection of complement activation through radiological imaging Adv Exp Med Biol 735 2013 271 282
3. J Zuber F Fakhouri LT Roumenina C Loirat V Fremeaux-Bacchi Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies Nat Rev Nephrol 8 2012 643 657
4. M Lemaire V Fremeaux-Bacchi F Schaefer Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome Nat Genet 45 2013 531 536
5. F Modde PA Agustian J Wittig Comprehensive analysis of glomerular mRNA expression of pro- and antithrombotic genes in atypical haemolytic-uremic syndrome (aHUS) Virchows Arch 462 2013 455 464
6. R Rabin F de Charro EQ-5D: a measure of health status from the EuroQol Group Ann Med 33 2001 337 343
7. CF Larrea F Cofan F Oppenheimer JM Campistol G Escolar M Lozano Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation Transplantation 89 2010 903 904
8. JN George DR Terrell KK Swisher SK Vesely Lessons learned from the Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome Registry J Clin Apher 23 2008 129 137
9. JN George How I treat patients with thrombotic thrombocytopenic purpura: 2010 Blood 116 2010 4060 4069 [Erratum, Blood 2011;117:5551.]
10. V Chatelet T Lobbedez V Fremeaux-Bacchi M Ficheux JP Ryckelynck B Hurault de Ligny Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report Transplant Proc 42 2010 4353 4355
11. AS Pickard NP Neary D Cella Estimation of minimally important differences in EQ-5D and VAS scores in cancer Health Qual Life Outcomes 5 2007 70 70 [Erratum, Health Qual Life Outcomes 2010;8:4.]